- Trials with a EudraCT protocol (297)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
297 result(s) found for: Relapsing-remitting.
Displaying page 5 of 15.
EudraCT Number: 2005-005985-35 | Sponsor Protocol Number: 1206.15 | Start Date*: 2006-08-29 | |||||||||||
Sponsor Name:Boehringer Ingelheim | |||||||||||||
Full Title: A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300... | |||||||||||||
Medical condition: Relapsing forms of Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002785-20 | Sponsor Protocol Number: EVIDIMS | Start Date*: 2011-09-19 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis | ||
Medical condition: Multiple Sclerosis and Clinical isolated Syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-015556-15 | Sponsor Protocol Number: 101MS325 | Start Date*: 2010-05-07 | |||||||||||
Sponsor Name:Biogen Idec Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... | |||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) PT (Completed) HU (Prematurely Ended) NL (Prematurely Ended) SI (Prematurely Ended) LV (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002633-20 | Sponsor Protocol Number: A4M105038 | Start Date*: 2006-11-17 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice dail... | |||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) FI (Completed) FR (Completed) AT (Completed) IT (Completed) LT (Prematurely Ended) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015318-23 | Sponsor Protocol Number: 205MS203 | Start Date*: 2010-01-21 | |||||||||||
Sponsor Name:Biogen Idec Ltd. | |||||||||||||
Full Title: A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects with Multiple Sclerosis Who Have Complete... | |||||||||||||
Medical condition: Relapsing-remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005559-46 | Sponsor Protocol Number: 205MS202 | Start Date*: 2009-01-23 | |||||||||||
Sponsor Name:Biogen Idec Ltd. | |||||||||||||
Full Title: A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT) | |||||||||||||
Medical condition: Relapsing-remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005008-24 | Sponsor Protocol Number: 08126 | Start Date*: 2011-07-07 | ||||||||||||||||
Sponsor Name:University of Nottingham | ||||||||||||||||||
Full Title: Worms for immune regulation of multiple sclerosis | ||||||||||||||||||
Medical condition: Relapsing Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-007549-29 | Sponsor Protocol Number: 2008-229 | Start Date*: 2009-06-09 | |||||||||||||||||||||
Sponsor Name:Danish Multiple Sclerosis Research Center | |||||||||||||||||||||||
Full Title: Trichuris suis Ova Therapy for Relapsing Multiple Sclerosis - a safety study | |||||||||||||||||||||||
Medical condition: Relapsing Multipel Sclerosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000253-92 | Sponsor Protocol Number: EHP-101-MS02 | Start Date*: 2022-10-14 | |||||||||||||||||||||
Sponsor Name:Emerald Health Pharmaceuticals Inc. | |||||||||||||||||||||||
Full Title: A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients with Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 | |||||||||||||||||||||||
Medical condition: Relapsing Forms of Multiple Sclerosis (RMS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001166-29 | Sponsor Protocol Number: inims-009 | Start Date*: 2020-03-18 | |||||||||||
Sponsor Name:University Medical Centre Hamburg-Eppendorf | |||||||||||||
Full Title: A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST) | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023560-40 | Sponsor Protocol Number: STU00010022 | Start Date*: 2011-03-23 | |||||||||||
Sponsor Name:Uppsala l�ns landsting | |||||||||||||
Full Title: Haematopoetic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004061-41 | Sponsor Protocol Number: 101-MS-321 | Start Date*: 2006-06-01 | |||||||||||
Sponsor Name:BIOGEN IDEC LTD | |||||||||||||
Full Title: An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... | |||||||||||||
Medical condition: Multiple sclerosis (MS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) FI (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005117-41 | Sponsor Protocol Number: ICP-CL-00112 | Start Date*: 2021-06-30 | |||||||||||
Sponsor Name:InnoCare Pharma, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, a... | |||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002820-10 | Sponsor Protocol Number: 205MS305 | Start Date*: 2017-03-13 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from Nataliz... | |||||||||||||
Medical condition: Remitting-Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012989-30 | Sponsor Protocol Number: MS-LAQ-301E | Start Date*: 2009-11-17 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd | |||||||||||||
Full Title: A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral la... | |||||||||||||
Medical condition: Laquinimod is developed for the treatment of relapsing remitting multiple sclerosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) EE (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) FR (Completed) LT (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006338-32 | Sponsor Protocol Number: WA21493 | Start Date*: 2008-05-06 | |||||||||||
Sponsor Name:Hoffman La Roche Ltd | |||||||||||||
Full Title: Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... | |||||||||||||
Medical condition: Relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) DE (Completed) ES (Completed) CZ (Completed) SK (Completed) DK (Completed) BE (Completed) NL (Completed) FI (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002082-19 | Sponsor Protocol Number: LAQ-MS-306 | Start Date*: 2013-11-25 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries, Ltd. | |||||||||||||
Full Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of... | |||||||||||||
Medical condition: Relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) SE (Prematurely Ended) FI (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000888-27 | Sponsor Protocol Number: GTR001 | Start Date*: 2011-09-21 | |||||||||||
Sponsor Name:Synthon BV | |||||||||||||
Full Title: Multi-centre, randomized, double-blind, placebo-controlled, parallel-group, 9 month, equivalence trial comparing the efficacy and safety and tolerability of GTR (Synthon BV) to Copaxone® (Teva) in ... | |||||||||||||
Medical condition: Relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) GB (Completed) DE (Completed) EE (Completed) GR (Prematurely Ended) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-007057-42 | Sponsor Protocol Number: A4M108119 | Start Date*: 2007-05-29 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||||||||||||||||||
Full Title: An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast | ||||||||||||||||||
Medical condition: relapsing forms of multiple sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-013333-24 | Sponsor Protocol Number: EMR 701048-525 | Start Date*: 2009-08-03 | |||||||||||
Sponsor Name:MERCK SERONO SPA | |||||||||||||
Full Title: Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inje... | |||||||||||||
Medical condition: RELAPSING MULTIPLE SCLEROSIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
